Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | WNT3 | P56703 | 2/20 | 0.37 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7404085 | 1.00 | ELANE (0.43) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL27539865 | 0.96 | KMT2A (0.44) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL3803839 | 0.86 | ENPP3 (0.41) | CYP2D6CYP1A2SCN4AENPP3ENPP1 | |
| SCHEMBL9538667 | 0.86 | ENPP3 (0.41) | ELANEHTR2CHTR2BSCN4AKMT2A | |
| SCHEMBL3060996 | 0.86 | ENPP3 (0.41) | CYP2D6CYP1A2SCN4AENPP3ENPP1 | |
| SCHEMBL8212865 | 0.83 | DPP4 (0.45) | DPP4TSHRHTR6KDM4E | |
| SCHEMBL7070285 | 0.80 | HTR2C (0.43) | ELANEHTR2CSCN4AKMT2AKDM4E | |
| SCHEMBL7754536 | 0.79 | HTR2C (0.46) | ELANECYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5717063 | 0.79 | ENPP3 (0.46) | KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL5586750 | 0.79 | PTGS2 (0.53) | CYP3A4KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| CN-104364258-B | Spirotetrahydro-benzothiophene derivatives for the treatment of neurodegenerative diseases | 阿瑞斯贸易股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-105051043-B | Novel heterocyclic derivatives as modulators of kinase activity | 默克专利有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106573932-A | Indazoles | 默克专利股份公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-104030987-B | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | 默克雪兰诺有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-103814016-B | Compositions and methods for producing pyrimidine and pyridine compounds having BTK inhibitory activity | 默克专利有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-104169258-B | novel heterocyclic carboxamides as modulators of kinase activity | 默克专利有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106458992-A | Pyridyl piperidines | 默克专利股份公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105980375-A | Pyrimidine imidazole amines as modulators of kinase activity | 默克专利有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-0925295-A1 | N-BENZENESULPHONYL-L-PROLINE DERIVATIVES AS BRADYKININ B2 AGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003503-A1 | N-BENZENESULPHONYL-L-PROLINE DERIVATIVES AS BRADYKININ B2 AGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ELANE 572/4885CYP3A4 4816/4885CYP2D6 4301/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ELANE 312/4885CYP3A4 4072/4885CYP2D6 3248/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | ELANE 4844/4885CYP3A4 3969/4885CYP2D6 3412/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | ELANE 416/4885CYP3A4 4168/4885CYP2D6 3547/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | ELANE 416/4885CYP3A4 4168/4885CYP2D6 3547/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ELANE 572/4885CYP3A4 4816/4885CYP2D6 4301/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | ELANE 416/4885CYP3A4 4168/4885CYP2D6 3547/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ELANE 572/4885CYP3A4 4816/4885CYP2D6 4301/4885 |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ELANE 572/4885CYP3A4 4816/4885CYP2D6 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.